Skip to Content

Anavex Life Sciences Corp AVXL

Morningstar Rating
$5.48 −0.23 (4.03%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AVXL is trading at a 323% premium.
Price
$5.65
Fair Value
$44.34
Uncertainty
Extreme
1-Star Price
$443.18
5-Star Price
$4.67
Economic Moat
Vsxs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVXL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.71
Day Range
$5.475.79
52-Week Range
$3.2510.45
Bid/Ask
$5.14 / $5.81
Market Cap
$463.84 Mil
Volume/Avg
692,310 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
40

Comparables

Valuation

Metric
AVXL
BIVI
RYTM
Price/Earnings (Normalized)
Price/Book Value
3.401.2449.07
Price/Sales
31.56
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
AVXL
BIVI
RYTM
Quick Ratio
14.982.433.99
Current Ratio
15.122.454.35
Interest Coverage
−9.50−17.19
Quick Ratio
AVXL
BIVI
RYTM

Profitability

Metric
AVXL
BIVI
RYTM
Return on Assets (Normalized)
−20.37%−115.58%−77.30%
Return on Equity (Normalized)
−22.09%−256.00%−148.97%
Return on Invested Capital (Normalized)
−26.33%−130.07%−146.66%
Return on Assets
AVXL
BIVI
RYTM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
GqgppwchmLwc$591.7 Bil
Vertex Pharmaceuticals Inc
VRTX
ZhhqtywBzbsgdg$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
FmshtmnGgxsrnb$117.2 Bil
Moderna Inc
MRNA
FsqyxsqZlzk$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
MgvsljrxxZdpqw$30.1 Bil
argenx SE ADR
ARGX
BncvhzmjWjrb$27.7 Bil
BioNTech SE ADR
BNTX
VljpjgvtFcvf$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
MzjmbjxlSxrct$16.0 Bil
United Therapeutics Corp
UTHR
ScfkjtmdLgfmz$14.6 Bil
Incyte Corp
INCY
FnyryjrzLrvfwx$13.0 Bil

Sponsor Center